IN BRIEF: Haleon initiates first tranche of GBP330 million buyback

Haleon PLC - Weybridge, Surrey-based consumer healthcare firm that spun out of GSK PLC in 2022 - ...

Alliance News 28 March, 2025 | 8:48AM
Email Form Facebook Twitter LinkedIn RSS

Haleon PLC - Weybridge, Surrey-based consumer healthcare firm that spun out of GSK PLC in 2022 - Commences up to GBP330 million share buyback programme. Says this represents the remainder of the GBP500 million allocated to buybacks in 2025, announced as part of its 2024 results in February. It follows the completion of Haleon's off-market repurchase of 44.2 million shares from Pfizer Inc for approximately GBP170 million, announced in March. Says the first tranche is for an up to GBP200 million consideration, commencing immediately and to end no later than June 26 this year. Haleon expects the buyback scheme to enhance its earnings per share, with Goldman Sachs hired to carry out the purchase of shares.

Current stock price: 386.10p, up 1.1% on Friday morning in London.

12-month change: up 16%

By Christopher Ward, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Haleon PLC 392.00 GBX 0.18
GSK PLC 1,469.00 GBX 0.48
Pfizer Inc 24.57 USD -3.06

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures